Li Zuo

657 total citations
35 papers, 451 citations indexed

About

Li Zuo is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Li Zuo has authored 35 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Li Zuo's work include Renal cell carcinoma treatment (7 papers), Ferroptosis and cancer prognosis (6 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Li Zuo is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Ferroptosis and cancer prognosis (6 papers) and Bladder and Urothelial Cancer Treatments (6 papers). Li Zuo collaborates with scholars based in China, United States and Japan. Li Zuo's co-authors include Shuyuan Yeh, Chawnshang Chang, Chao Wang, Xingang Cui, Zhenyu Ou, Le Tao, Chuanmin Chu, Lifeng Zhang, Yu Liu and Hong‐Ru Lin and has published in prestigious journals such as Oncogene, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Li Zuo

32 papers receiving 448 citations

Peers

Countries citing papers authored by Li Zuo

Since Specialization

Citations

This map shows the geographic impact of Li Zuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Zuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Zuo more than expected).

Fields of papers citing papers by Li Zuo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li Zuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Zuo. The network helps show where Li Zuo may publish in the future.

Co-authorship network of co-authors of Li Zuo

This figure shows the co-authorship network connecting the top 25 collaborators of Li Zuo. A scholar is included among the top collaborators of Li Zuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li Zuo. Li Zuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	OSM May Serve as a Biomarker of Poor Prognosis in Clear Cell Renal Cell Carcinoma and Promote Tumor Cell Invasion and Migration 2023 ·International Journal of Genomics ·(unknown), Yin Chen, (unknown), Li Zuo, Lifeng Zhang	0
2	Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study 2022 ·Cell Death and Disease ·Wenjin Chen, Hao Cao, Jianwei Cao, Li Zuo, Fajun Qu, Da Xu, Hao Zhang, Haiyi Gong, Jiaxin Chen, Jianqing Ye, Sishun Gan, Zhou Wang, Dawei Zhu, Xiuwu Pan, Xingang Cui	14
3	TRIM47 is a novel endothelial activation factor that aggravates lipopolysaccharide-induced acute lung injury in mice via K63-linked ubiquitination of TRAF2 2022 ·Signal Transduction and Targeted Therapy ·Yisong Qian, Ziwei Wang, Hong‐Ru Lin, Tianhua Lei, Zhou Zhou, (unknown), (unknown), Li Zuo, Jie Wu, Yu Liu, Lingfang Wang, Xiao‐Hui Guan, Ke‐Yu Deng, Mingui Fu, Hongbo Xin	69
4	Identification of a Novel Ferroptosis-Related Gene Signature for Prediction of Prognosis in Bladder Urothelial Carcinoma 2021 ·Bladder Cancer ·(unknown), Xiao Zhou, Lei Zhang, (unknown), (unknown), (unknown), Li Zuo, Lifeng Zhang	2
5	RNF43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma 2021 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Dawei Zhu, Lei Zhang, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Chao Wang, Xingang Cui, Li Zuo	7
6	TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination 2021 ·Cancer Cell International ·Jiaxin Chen, Da Xu, Jianwei Cao, Li Zuo, Zhitao Han, Yijun Tian, Chuanmin Chu, Zhou Wang, Xiuwu Pan, Xingang Cui	28
7	Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer 2021 ·Scientific Reports ·Tao Peng, Yangyang Sun, (unknown), Ze Zhang, (unknown), Hao Wu, Wei Zhang, Wei Yuan, Li Zuo, Li Shi, Lifeng Zhang, Xiaoli Zhou, Yuanyuan Mi	12
8	R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway 2021 ·Molecular Therapy — Oncolytics ·Yuan Gao, Xiwu Ouyang, Li Zuo, Yao Xiao, Yin Sun, Chawnshang Chang, Xihu Qin, Shuyuan Yeh	18
9	MiR-25 regulates cell proliferation and metastasis in bladder urothelial carcinoma 2021 ·Journal of Cancer ·Jinzhuo Ning, Chuanmin Chu, Yang Du, Li Zuo	3
10	Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma 2020 ·Cell Death and Disease ·Chao Wang, Yuning Wang, (unknown), (unknown), Sishun Gan, (unknown), Jing Zhang, Li Zuo, (unknown), Xingang Cui	29
11	Targeting a positive regulatory loop in the tumor-macrophage interaction impairs the progression of clear cell renal cell carcinoma 2020 ·Cell Death and Differentiation ·Chao Wang, Yuning Wang, (unknown), Jianqing Ye, Chuanmin Chu, Li Zuo, Jing Zhang, Xingang Cui	31
12	Prophylactic Urethrectomy Could Further Shorten the Female Bladder Cancer Recurrence and Metastasis 2020 ·Lifeng Zhang, (unknown), (unknown), Jiasheng Chen, Li Zuo	1
13	No association between three polymorphisms (rs1800629, rs361525 and rs1799724) in the tumor necrosis factor-α gene and susceptibility to prostate cancer: a comprehensive meta-analysis 2020 ·Hereditas ·Lei Yin, (unknown), Hongwei Jing, Hongyuan Yu, Li Zuo, Tao Liu	3
14	Relationship between measured and prescribed dialysate sodium in haemodialysis: a systematic review and meta-analysis 2020 ·Nephrology Dialysis Transplantation ·Jack Kit‐Chung Ng, Brendan Smyth, Mark R. Marshall, Amy Kang, J Pintér, Abhinav Bassi, Rathika Krishnasamy, Patrick Rossignol, Michael V. Rocco, Li Zuo, Vivekanand Jha, Carmel M. Hawley, Peter G. Kerr, Gian Luca Di Tanna, Mark Woodward, (unknown)	7
15	Estrogen receptor β promotes bladder cancer growth and invasion via alteration of miR-92a/DAB2IP signals 2018 ·Experimental & Molecular Medicine ·Zhenyu Ou, Yongjie Wang, Jinbo Chen, Le Tao, Li Zuo, Deepak M. Sahasrabudhe, Jean Joseph, Long Wang, Shuyuan Yeh	45
16	Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals 2018 ·Cancer Letters ·Le Tao, Jianxin Qiu, Spencer Slavin, Zhenyu Ou, Zhihong Liu, Jifu Ge, Li Zuo, Elizabeth A. Guancial, Edward M. Messing, Chawnshang Chang, Shuyuan Yeh	32
17	Bilateral blindness with secondary retinitis pigmentosa following postoperative docetaxel and platinum combination chemotherapy in primary small-cell carcinoma of the endometrium: An unusual case report and review of the literature 2017 ·Molecular and Clinical Oncology ·Qiong-Lan Tang, Jia Liu, Li Zuo, (unknown), (unknown), Xiaoxia Jiang, Xuefeng Jiang	2
18	Systematic review/Meta-analysis Association of a common genetic variant in prostate stem cell antigen with cancer risk 2014 ·Archives of Medical Science ·Li Zuo, (unknown), (unknown), (unknown), (unknown), Jun He, (unknown)	6
19	Association between IL13 gene polymorphisms and susceptibility to cancer: A meta-analysis 2012 ·Gene ·Tong Su, Yuanyuan Mi, Lifeng Zhang, Shangqian Wang, (unknown), Li Shi, (unknown), Xiaopeng Wu, Wei Zhang, Li Zuo, (unknown)	15
20	In vitro phosphate-binding ability of calcium-based agents is augmented by co-administration of activated charcoal 2012 ·Clinical Nephrology ·(unknown), (unknown), Li Zuo	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact